Clinical trial
Androgen Suppression and Radiation With/Out Docetaxel in High-Risk Localized Prostate Cancer
NCT00651326
Study timeline
Study start (actual)2008-06-02Date precision: day
Registry last updated2023-08-04
Observed by CureCurrent2026-10-07
Recorded dates are source observations, not predictions. Missing milestones are not estimated.
Conditions
Prostate Cancerunresolved
Interventions
bicalutamideDRUG · verified · RxNorm: bicalutamide
buserelinDRUG · verified · RxNorm: buserelin
flutamideDRUG · verified · RxNorm: flutamide
goserelinDRUG · verified · RxNorm: goserelin
leuprolide acetateDRUG · verified · RxNorm: leuprolide acetate
neoadjuvant therapyPROCEDURE
quality-of-life assessmentPROCEDURE
radiation therapyRADIATION
DocetaxelDRUG · verified · RxNorm: docetaxel
Sponsors & collaborators
NCIC Clinical Trials Grouplead sponsor
Registry source
Open the source record to verify current eligibility, contacts, locations and registry updates.
Open NCT00651326 on ClinicalTrials.gov ↗Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.